MedTrace Logo

Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation

NCT06444087 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 192

Last updated 2026-01-29

No results posted yet for this study

Summary

The primary objective of this non-interventional study is to describe the evolution of Hidradenitis suppurativa (HS) symptoms 12 months after secukinumab initiation based on the patients' assessment of pain, oozing, and bad smell.

Conditions

Interventions

OTHER

secukinumab

This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-17
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06444087 on ClinicalTrials.gov